| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
RPGLIFE Stock Overview
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally.
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹619.85 |
| 52 Week High | ₹752.45 |
| 52 Week Low | ₹341.90 |
| Beta | 0.77 |
| 1 Month Change | -8.60% |
| 3 Month Change | 23.61% |
| 1 Year Change | 70.64% |
| 3 Year Change | 164.89% |
| 5 Year Change | 28.92% |
| Change since IPO | 1,280.51% |
Recent News & Updates
Shareholders May Be More Conservative With RPG Life Sciences Limited's (NSE:RPGLIFE) CEO Compensation For Now
Performance at RPG Life Sciences Limited ( NSE:RPGLIFE ) has been reasonably good and CEO Yugal Kishor Sikri has done a...
A Look At The Intrinsic Value Of RPG Life Sciences Limited (NSE:RPGLIFE)
How far off is RPG Life Sciences Limited ( NSE:RPGLIFE ) from its intrinsic value? Using the most recent financial...
Shareholder Returns
| RPGLIFE | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.6% | 0.7% | -0.6% |
| 1Y | 70.6% | 16.7% | 47.7% |
Return vs Industry: RPGLIFE exceeded the Indian Pharmaceuticals industry which returned 16.5% over the past year.
Return vs Market: RPGLIFE exceeded the Indian Market which returned 48% over the past year.
Price Volatility
| RPGLIFE volatility | |
|---|---|
| RPGLIFE Average Weekly Movement | 8.4% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.8% |
Stable Share Price: RPGLIFE is more volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: RPGLIFE's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 1,107 | Yugal Kishor Sikri | https://www.rpglifesciences.com |
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmentics, anti-convulsant, anti-spasmodic, etc. It also provides generics primarily in the area of immunosuppressant therapy; and finished dosage formulations for various therapies, such as nephrology, oncology, urology, respiratory, vitamins and minerals, gastro intestinal, pain management, cardio-vascular, etc. primarily under the Lomotil, Lomofen+, Naprosyn, Azoran, Aldactone, and Serenace brand names. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008.
RPG Life Sciences Fundamentals Summary
| RPGLIFE fundamental statistics | |
|---|---|
| Market Cap | ₹10.26b |
| Earnings (TTM) | ₹491.20m |
| Revenue (TTM) | ₹4.21b |
20.9x
P/E Ratio2.4x
P/S RatioIs RPGLIFE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RPGLIFE income statement (TTM) | |
|---|---|
| Revenue | ₹4.21b |
| Cost of Revenue | ₹1.45b |
| Gross Profit | ₹2.76b |
| Expenses | ₹2.27b |
| Earnings | ₹491.20m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 29.70 |
| Gross Margin | 65.63% |
| Net Profit Margin | 11.66% |
| Debt/Equity Ratio | 0.06% |
How did RPGLIFE perform over the long term?
See historical performance and comparisonDividends
1.2%
Current Dividend Yield24%
Payout RatioValuation
Is RPG Life Sciences undervalued compared to its fair value and its price relative to the market?
34.0%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: RPGLIFE (₹620.2) is trading below our estimate of fair value (₹939.2)
Significantly Below Fair Value: RPGLIFE is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: RPGLIFE is good value based on its PE Ratio (20.9x) compared to the Indian Pharmaceuticals industry average (21.2x).
PE vs Market: RPGLIFE is poor value based on its PE Ratio (20.9x) compared to the Indian market (19.1x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RPGLIFE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RPGLIFE is overvalued based on its PB Ratio (4.4x) compared to the IN Pharmaceuticals industry average (2.7x).
Future Growth
How is RPG Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
20.5%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as RPG Life Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has RPG Life Sciences performed over the past 5 years?
27.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RPGLIFE has high quality earnings.
Growing Profit Margin: RPGLIFE's current net profit margins (11.7%) are higher than last year (8.4%).
Past Earnings Growth Analysis
Earnings Trend: RPGLIFE's earnings have grown significantly by 27% per year over the past 5 years.
Accelerating Growth: RPGLIFE's earnings growth over the past year (57.9%) exceeds its 5-year average (27% per year).
Earnings vs Industry: RPGLIFE earnings growth over the past year (57.9%) exceeded the Pharmaceuticals industry 31.7%.
Return on Equity
High ROE: RPGLIFE's Return on Equity (21%) is considered high.
Financial Health
How is RPG Life Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: RPGLIFE's short term assets (₹2.0B) exceed its short term liabilities (₹844.6M).
Long Term Liabilities: RPGLIFE's short term assets (₹2.0B) exceed its long term liabilities (₹90.2M).
Debt to Equity History and Analysis
Debt Level: RPGLIFE has more cash than its total debt.
Reducing Debt: RPGLIFE's debt to equity ratio has reduced from 11.8% to 0.06% over the past 5 years.
Debt Coverage: RPGLIFE's debt is well covered by operating cash flow (53840%).
Interest Coverage: RPGLIFE's interest payments on its debt are well covered by EBIT (290.7x coverage).
Balance Sheet
Dividend
What is RPG Life Sciences's current dividend yield, its reliability and sustainability?
1.16%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: RPGLIFE's dividend (1.16%) is higher than the bottom 25% of dividend payers in the Indian market (0.35%).
High Dividend: RPGLIFE's dividend (1.16%) is low compared to the top 25% of dividend payers in the Indian market (1.46%).
Stability and Growth of Payments
Stable Dividend: RPGLIFE's dividend payments have been volatile in the past 10 years.
Growing Dividend: RPGLIFE's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (24.2%), RPGLIFE's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.1yrs
Average management tenure
CEO
Yugal Kishor Sikri (64 yo)
3.08yrs
Tenure
₹39,147,000
Compensation
Mr. Yugal Kishor Choturam Sikri has been Managing Director and Director at RPG Life Sciences Limited since October 1, 2018 He served as an Independent & Non-Executive Director at RPG Life Sciences Limited...
CEO Compensation Analysis
Compensation vs Market: Yugal Kishor's total compensation ($USD524.70K) is above average for companies of similar size in the Indian market ($USD39.49K).
Compensation vs Earnings: Yugal Kishor's compensation has increased by more than 20% in the past year.
Leadership Team
Experienced Management: RPGLIFE's management team is considered experienced (3.1 years average tenure).
Board Members
Experienced Board: RPGLIFE's board of directors are considered experienced (7.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
RPG Life Sciences Limited's employee growth, exchange listings and data sources
Key Information
- Name: RPG Life Sciences Limited
- Ticker: RPGLIFE
- Exchange: NSEI
- Founded: 1968
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹10.257b
- Shares outstanding: 16.54m
- Website: https://www.rpglifesciences.com
Number of Employees
Location
- RPG Life Sciences Limited
- RPG HOUSE
- 463, Dr. Annie Besant Road
- Mumbai
- Maharashtra
- 400030
- India
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/11/26 12:07 |
| End of Day Share Price | 2021/11/26 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2021/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.